An experimental treatment has shown promise in lowering bad cholesterol, offering hope for people at risk of heart disease but who cannot tolerate drugs known as statins, researchers said Sunday. The therapy developed by Amgen pharmaceuticals is known as evolocumab. Evolocumab is part of a new class of drugs known as PCSK9 inhibitors, which suppress a gene involved with cholesterol regulation in the liver. Research from two separate phase III trials released at the American College of Cardiology annual meeting showed it was effective in lowering LDL, or bad cholesterol, with few side effects.
via Health News Headlines - Yahoo News http://ift.tt/1fFrobP
No comments:
Post a Comment